Interstitial lung diseases

M Wijsenbeek, A Suzuki, TM Maher - The Lancet, 2022 - thelancet.com
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development

P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

[HTML][HTML] Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation

LE Leard, AM Holm, M Valapour, AR Glanville… - The Journal of Heart and …, 2021 - Elsevier
Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

PM George, P Spagnolo, M Kreuter… - The lancet Respiratory …, 2020 - thelancet.com
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

P Spagnolo, O Distler, CJ Ryerson… - Annals of the rheumatic …, 2021 - Elsevier
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct
aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and …

The natural history of progressive fibrosing interstitial lung diseases

M Kolb, M Vašáková - Respiratory research, 2019 - Springer
A proportion of patients with certain types of interstitial lung disease (ILD), including chronic
hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a …

Immune mechanisms in fibrotic interstitial lung disease

M Kamiya, H Carter, MS Espindola, TJ Doyle, JS Lee… - Cell, 2024 - cell.com
Fibrotic interstitial lung diseases (fILDs) have poor survival rates and lack effective therapies.
Despite evidence for immune mechanisms in lung fibrosis, immunotherapies have been …

Treatment of fibrotic interstitial lung disease: current approaches and future directions

KA Johannson, N Chaudhuri, A Adegunsoye… - The Lancet, 2021 - thelancet.com
Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations

T Shao, X Shi, S Yang, W Zhang, X Li, J Shu… - Frontiers in …, 2021 - frontiersin.org
Connective tissue disease (CTD) related interstitial lung disease (CTD-ILD) is one of the
leading causes of morbidity and mortality of CTD. Clinically, CTD-ILD is highly heterogenous …

Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows

G Cassone, A Manfredi, C Vacchi, F Luppi… - Journal of clinical …, 2020 - mdpi.com
Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary …